Wang Yan, Shi Jian-Gong, Wang Mu-Zou, Che Chun-Tao, Yeung John H K
School of Chinese Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Life Sci. 2007 Sep 1;81(12):1016-23. doi: 10.1016/j.lfs.2007.08.010. Epub 2007 Aug 17.
1-Hydroxy-2, 3, 5-trimethoxyxanthone (HM-1) is a xanthone isolated from Halenia elliptica, a Tibetan medicinal herb. HM-1 (0.33-42.1 microM) produced a concentration-dependent relaxation in rat coronary artery rings pre-contracted with 1 microM 5-hydroxytryptamine (5-HT), with an EC(50) of 1.67+/-0.27 microM. Removal of the endothelium significantly affected the vasodilator potency of HM-1, resulting in 46% decrease in E(max) value. The endothelium-dependent effects of HM-1 was confirmed when its vasorelaxant effect was inhibited after addition of nitric oxide synthase (NOS) inhibitor N(omega)-nitro-l-arginine methyl ester (100 microM) or the soluble guanylate cyclase inhibitor 1H-[1, 2, 4] oxadiazolo [4,3-alpha] quinoxalin-1-one (ODQ, 10 microM). Atropine (100 nM), flurbiprofen (10 microM), propranolol (100 microM), pyrilamine (10 microM), cimetidine (10 microM) and SQ22536 (100 microM) had no effect on the vasorelaxant activity of HM-1 indicated the non-involvement of other receptor/enzyme systems. In endothelium-denuded coronary artery rings, the vasorelaxant effect of HM-1 was unaffected by potassium channel blockers such as tetraethylammonium (10 mM), iberiotoxin (100 nM), barium chloride (100 microM) and 4-aminopyridine (1 mM). The involvement of Ca(2+) channel in 5-HT-primed artery ring preparations incubated with Ca(2+)-free buffer was confirmed when HM-1 (9.93 microM) partially abolished the CaCl(2)-induced vasoconstriction (87% inhibition in intact-endothelium artery rings; 50% inhibition in endothelium-denuded rings). In the KCl-primed preparations incubated with Ca(2+)-free buffer, HM-1 (9.93 microM) produced a 27.3% inhibition in endothelium-denuded rings. HM-1 (3.31-33.1 microM) had minimal relaxant effects (14.4%-20.3%) on the contractile response generated by 10 microM phorbol 12,13-diacetate (PDA) in Ca(2+)-free solutions, suggesting minimal effects on intracellular Ca(2+) mechanisms. These findings suggest the vasodilator action of HM-1 involved both an endothelium-dependent mechanism involving NO and an endothelium-independent mechanism by inhibiting Ca(2+) influx through L-type voltage-operated Ca(2+) channels; a minor contribution to the effects of HM-1 may be related to inhibition of the protein kinase C-mediated release of intracellular Ca(2+) stores.
1-羟基-2,3,5-三甲氧基呫吨酮(HM-1)是从藏药椭圆叶花锚中分离得到的一种呫吨酮。HM-1(0.33 - 42.1微摩尔)对用1微摩尔5-羟色胺(5-HT)预收缩的大鼠冠状动脉环产生浓度依赖性舒张作用,半数有效浓度(EC50)为1.67±0.27微摩尔。去除内皮显著影响HM-1的血管舒张效力,导致最大效应(E(max))值降低46%。当加入一氧化氮合酶(NOS)抑制剂Nω-硝基-L-精氨酸甲酯(100微摩尔)或可溶性鸟苷酸环化酶抑制剂1H-[1,2,4]恶二唑并[4,3-α]喹喔啉-1-酮(ODQ,10微摩尔)后,HM-1的血管舒张作用受到抑制,从而证实了其内皮依赖性作用。阿托品(100纳摩尔)、氟比洛芬(10微摩尔)、普萘洛尔(100微摩尔)、吡拉明(10微摩尔)、西咪替丁(10微摩尔)和SQ2253(100微摩尔)对HM-1的血管舒张活性无影响,表明其他受体/酶系统未参与其中。在去内皮的冠状动脉环中,HM-1的血管舒张作用不受钾通道阻滞剂如四乙铵(10毫摩尔)、iberiotoxin(100纳摩尔)、氯化钡(100微摩尔)和4-氨基吡啶(1毫摩尔)的影响。当HM-1(9.93微摩尔)部分消除氯化钙诱导的血管收缩时(完整内皮动脉环中抑制87%;去内皮环中抑制50%),证实了在无钙缓冲液中孵育的5-HT预收缩动脉环制剂中钙通道的参与。在无钙缓冲液中孵育的氯化钾预收缩制剂中,HM-1(9.93微摩尔)在去内皮环中产生27.3%的抑制作用。HM-1(3.31 - 33.1微摩尔)对无钙溶液中10微摩尔佛波醇12,13-二乙酸酯(PDA)产生的收缩反应的舒张作用最小(14.4% - 20.3%),表明对细胞内钙机制的影响最小。这些发现表明,HM-1的血管舒张作用涉及一种依赖内皮的机制,该机制涉及一氧化氮,以及一种不依赖内皮的机制,即通过抑制L型电压门控钙通道的钙内流;HM-1作用的微小贡献可能与抑制蛋白激酶C介导的细胞内钙储存释放有关。